Frequent emergence of resistance mutations following complex intra-host genomic dynamics in SARS-CoV-2 patients receiving Sotrovimab
R. P. Cabrera, F. Tejerina, A. M. Salinas, M. Ferris, C. Veintimilla, P. Catalan, G. R. Macias, R. Alonso, P. Munoz, D. Garcia de Viedma, L. Perez-Lago
This study tracks resistance mutation emergence in SARS-CoV-2 patients treated with Sotrovimab, finding 68% resistance in BA.5 lineage with rapid onset and complex mutation dynamics.
Antimicrobial Agents and Chemotherapy · Jul 18, 2023Peer-reviewedMicrobiology